BobcatBio

Bobcat Bio is a biotechnology company focused on developing next-generation cell therapies for oncology and autoimmune diseases. The company was founded by a team of industry veterans, including former leadership from Kite Pharma, who played pivotal roles in the development of early CAR-T successes. Bobcat Bio utilizes a proprietary platform designed to enhance the fitness, persistence, and potency of engineered immune cells through epigenetic reprogramming. By addressing the fundamental biological limitations of current cell therapies, the company aims to create treatments that are more effective against solid tumors and chronic inflammatory conditions. Headquartered in Cambridge, Massachusetts, Bobcat Bio is backed by leading venture capital firms such as ARCH Venture Partners and Westlake Village BioPartners. The company is currently in the pre-clinical stage, advancing a pipeline of internal programs while refining its cell engineering technologies.